Biostat's Research and Development Center has prepared a randomization system for a clinical trial being conducted in the United States by Neuro Device Group S.A.

NeuroDevice Group is conducting a clinical trial in the United States related to the treatment of patients with post-stroke aphasia. Post-stroke aphasia is the loss of the ability, and in some cases the understanding of speech, caused by damage to the brain structure as a result of a stroke.

The sponsor of the aforementioned study invited Biostat Research and Development Center to cooperate.

We were responsible for providing the randomization system. In a nutshell, a randomization system allows the random assignment of study participants to the various arms of a study. A well-prepared randomization tool ultimately has a major impact on the reliability of the results of a clinical trial, 

 explains Edyta Klemba - Pharma Division Director at Biostat.

Rafal Piszczek - CEO of Biostat adds:

We are pleased that our competence and experience have been recognized and that we can participate in clinical trials not only in Europe, but also in the United States. Thanks to such projects, Biostat is becoming an increasingly serious player on the clinical trials market, 

Rafal Piszczek emphasizes.

NeuroDevice Group specializes in projects in various areas of neuroscience. The company develops technologies that enable innovative therapies for patients with central nervous system disorders using breakthroughs in brain function. Among other things, the company boasts the development of neurostimulators using tES (transcranial electric stimulation) technology.